XNAS
IPSC
Market cap54mUSD
Jun 12, Last price
0.60USD
1D
-1.01%
1Q
0.62%
IPO
-97.61%
Name
Century Therapeutics Inc
Chart & Performance
P/E
—
P/S
7.85
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.48%
Rev. gr., 5y
%
Revenues
7m
+194.81%
Net income
-127m
L-7.40%
CFO
-110m
L+24.66%
Profile
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 6,589 194.81% | 2,235 -57.01% | 5,199 | |||
Cost of revenue | 140,399 | 140,460 | 149,101 | |||
Unusual Expense (Income) | ||||||
NOPBT | (133,810) | (138,225) | (143,902) | |||
NOPBT Margin | ||||||
Operating Taxes | 1,790 | 1,881 | 91 | |||
Tax Rate | ||||||
NOPAT | (135,600) | (140,106) | (143,993) | |||
Net income | (126,566) -7.40% | (136,673) 4.38% | (130,932) 36.64% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 74,563 | 516 | 27,158 | |||
BB yield | -93.87% | -0.26% | -9.17% | |||
| Debt | ||||||
Debt current | 1,513 | 6,977 | ||||
Long-term debt | 97,920 | 93,316 | 81,610 | |||
Deferred revenue | 111,381 | 110,834 | ||||
Other long-term liabilities | 8,738 | 56 | 718 | |||
Net debt | (122,190) | (167,005) | (278,765) | |||
| Cash flow | ||||||
Cash from operating activities | (110,135) | (88,348) | 14,052 | |||
CAPEX | (13,736) | (30,604) | ||||
Cash from investing activities | 47,482 | 61,132 | (13,128) | |||
Cash from financing activities | 74,563 | (9,725) | 27,158 | |||
FCF | (134,366) | (120,457) | (185,902) | |||
| Balance | ||||||
Cash | 189,292 | 172,738 | 315,498 | |||
Long term investments | 30,818 | 89,096 | 51,854 | |||
Excess cash | 219,781 | 261,722 | 367,092 | |||
Stockholders' equity | (782,004) | (655,657) | (521,554) | |||
Invested Capital | 1,001,064 | 1,000,015 | 985,258 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 78,649 | 59,314 | 57,756 | |||
Price | 1.01 -69.58% | 3.32 -35.28% | 5.13 -67.65% | |||
Market cap | 79,435 -59.66% | 196,924 -33.54% | 296,287 -66.04% | |||
EV | (42,755) | 29,919 | 17,522 | |||
EBITDA | (120,506) | (125,181) | (135,462) | |||
EV/EBITDA | 0.35 | |||||
Interest | 540 | 1,105 | ||||
Interest/NOPBT | ||||||